[15].Wang L, Yang C, Xie C, et al. Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials. Cancer Sci. 2019;110(3):1064-1075. doi:10.1111/cas.13947 [16].Li N, Bu H, Liu J, et al. An Open-label, Multicenter, Single-...
3.Jiang X, Li W, Li X, et al. Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer. Cancer Manag Res 2019;11:4371-4390.bioSeedin柏思荟是生物医药行业的交流互动和知识服务平台以优质的知识分享和领先的用户体验帮助更多的生物医药人自我优化与提升旨在汇聚行业领袖与...
[32]Cho HW, Kim JW, Park JY, et al. 820TiP A randomized phase Ⅱ study of secondary cytoreductive surgery (CRS) in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance (KGOG 3067/SOCCER-P...
[15].Wang L, Yang C, Xie C, et al. Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials. Cancer Sci. 2019;110(3):1064-1075. doi:10.1111/cas.13947 [16].Li N, Bu H, Liu J, et al. An Open-label, Multicenter, Single-...
5.Artios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer - Artios Pharma 6.Yousefzadeh, M. J.; Wyatt, D. W.; Takata, K.-I.; Mu, Y.; Hensley, ...
今天小编有幸邀请到北京协和医院杨佳欣教授分享:2018年2月发表在Current opinion in obstetrics & gynecology的一篇综述(Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer),主要探讨PARP抑制剂联合其他治疗的作用机理和研究进展。
ChemotherapyThe first clinical trial of a PARP inhibitor was designed shortly before the concept of synthetic lethality emerged. Single agent activity was not anticipated and, based upon pre-clinical evaluation, PARP inhibition was envisaged as a means to overcome tumour resistance to chemotherapy. The...
POLQ是癌症治疗中颇具前景的靶标,科学界和工业界也在积极开发POLQ抑制剂,2021年8月5日,Artios Pharma在clinicaltrials网站公示了First-in-class药物ART4215的临床登记信息,ART4215成为全球首个进入临床研究的,高选择性的口服小分子靶向Polθ聚合酶结构域POLQ抑制剂。
[2]PARP1 inhibitor HS-10502, from https://www.cancer.gov/publications/dictionaries/cancer-drug/def/parp1-inhibitor-hs-10502 [3]ClinicalTrials官网. From https://clinicaltrials.gov/study/NCT05740956?term=HS-10502&rank=1 （转自：医药观澜）
Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials. Cancer Letters 2017; 386: 47-56 【14】Hopkins TA, Shi Y, Rodriguez LE, et al. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and ...